EP300 and Familial prostate cancer: Analysis of genomic and clinical data in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) has revealed that the HAT P300 and its target H3K18Ac increase during prostate cancer progression, while the HDAC SIRT2 decreases.